DNA methylation mediates the effect of BMI on insulin-treated gestational diabetes mellitus

WANG Ting-ting; SU Ping; SUN Xiao-ru; YU Yuan-yuan; LI Hong-kai; XUE Fu-zhong

doi:10.16462/j.cnki.zhjbkz.2021.06.006

Volume 25 Issue 6

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(6): 650-655

WANG Ting-ting, SU Ping, SUN Xiao-ru, YU Yuan-yuan, LI Hong-kai, XUE Fu-zhong. DNA methylation mediates the effect of BMI on insulin-treated gestational diabetes mellitus[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(6): 650-655. doi: 10.16462/j.cnki.zhjbkz.2021.06.006

Citation:

WANG Ting-ting, SU Ping, SUN Xiao-ru, YU Yuan-yuan, LI Hong-kai, XUE Fu-zhong. DNA methylation mediates the effect of BMI on insulin-treated gestational diabetes mellitus[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(6): 650-655. doi: 10.16462/j.cnki.zhjbkz.2021.06.006

Citation:

WANG Ting-ting, SU Ping, SUN Xiao-ru, YU Yuan-yuan, LI Hong-kai, XUE Fu-zhong. DNA methylation mediates the effect of BMI on insulin-treated gestational diabetes mellitus[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(6): 650-655. doi: 10.16462/j.cnki.zhjbkz.2021.06.006

PDF( 820 KB)

DNA methylation mediates the effect of BMI on insulin-treated gestational diabetes mellitus

doi: 10.16462/j.cnki.zhjbkz.2021.06.006

1.
Institute of Medical Sciences, The Second Hospital of Shandong University, Jinan 250033, China
2.
Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Institute of Healch and Medical Research, Shandong University, Jinan 250012, China

Funds:

National Key Research and Development Program 2020YFC2003500

National Natural Science Foundation of China 81773547

National Natural Science Foundation of China 82003557

National Natural Science Foundation of Shandong Province ZR2019ZD02

National Natural Science Foundation of Shandong Province ZR2019PH041

More Information

Corresponding author: LI Hong-kai, E-mail: lihongkaiyouxiang@163.com; XUE Fu-zhong, E-mail: xuefzh@sdu.edu.cn
Received Date: 2021-04-25
Rev Recd Date: 2021-05-18
Publish Date: 2021-06-10

Abstract

Abstract

Objective To explore the mediate role of DNA methylation between body mass index (BMI) and insulin-treated gestational diabetes mellitus (I-GDM) and further estimate its mediation effect. Methods Based on Gene Expression Omnibus (GEO) data repository (accession number GSE88929), obstetricians collected 44 I-GDM and 64 controls, which included a total of 212 991 cytosine-phosphate-guanine pairs of nucleotides (CpG) sites. A causal inference test (CIT) was used to select potential mediator of CpG sites. Furthermore, after adjusting for confounding factors including maternal age, fetal sex, and gestational age, we estimated the mediation effect of BMI on I-GDM by CpG sites. Results In CIT process, step 1 results showed that BMI was associated with I-GDM (OR=1.057, 95% CI: 1.014-1.105, P=0.010). Step 2 results indicated that 6 348 CpG after adopting FDR correction were associated with I-GDM conditional on BMI. Step 3 results manifested that 529 CpG were associated with BMI adjusting for I-GDM. Step 4 results showed that I-GDM was independent of BMI after adjusting 6 CpG. Therefore, CIT detected 6 CpG sites (cg00542041, cg08589721, cg25775742, cg15819225, cg26824326, cg15110463) as mediators between BMI and I-GDM. The above 6 CpG showed significant mediation effects by a causal inference model of mediation analysis. Conclusion Our research identified 6 DNA methylation CpG sites, which represent a potential mediation relationship between BMI and I-GDM. These findings suggest that the 6 CpG may serve as novel biomarkers and provide an essential reference for studying the complex biological mechanism between BMI and I-GDM.
- Insulin-treated gestational diabetes mellitus,
- BMI,
- Causal inference test,
- Mediation effect

FullText(HTML)

References(29)

References

[1]	Reece EA, Leguizamón G, Wiznitzer A. Gestational diabetes: the need for a common ground[J]. Lancet, 2009, 373(9677): 1789-1797. DOI: 10.1016/S0140-6736(9)60515-8.
[2]	Wang L, Yan B, Shi X, et al. Age at menarche and risk of gestational diabetes mellitus: a population-based study in Xiamen, China[J]. BMC Pregnancy Childbirth, 2019, 19(1): 138. DOI: 10.1186/s12884-019-2287-6.
[3]	Haertle L, El Hajj N, Dittrich M, et al. Epigenetic signatures of gestational diabetes mellitus on cord blood methylation[J]. Clin Epigenetics, 2017, 9: 28. DOI: 10.1186/s13148-017-0329-3.
[4]	Martin KE, Grivell RM, Yelland LN, et al. The influence of maternal BMI and gestational diabetes on pregnancy outcome[J]. Diabetes Res Clin Pract, 2015, 108(3): 508-513. DOI: 10.1016/j.diabres.2014.12.015.
[5]	Yong HY, Mohd Shariff Z, Mohd Yusof BN, et al. Independent and combined effects of age, body mass index and gestational weight gain on the risk of gestational diabetes mellitus[J]. Sci Rep, 2020, 10(1): 8486. DOI: 10.1038/s41598-020-65251-2.
[6]	Najafi F, Hasani J, Izadi N, et al. The effect of prepregnancy body mass index on the risk of gestational diabetes mellitus: a systematic review and dose-response meta-analysis[J]. Obes Rev, 2019, 20(3): 472-486. DOI: 10.1111/obr.12803.
[7]	Reichetzeder C, Dwi Putra SE, Pfab T, et al. Increased global placental DNA methylation levels are associated with gestational diabetes[J]. Clin Epigenetics, 2016, 8: 82. DOI: 10.1186/s13148-016-0247-9.
[8]	Torloni MR, Betrán AP, Horta BL, et al. Prepregnancy BMI and the risk of gestational diabetes: a systematic review of the literature with meta-analysis[J]. Obes Rev, 2009, 10(2): 194-203. DOI: 10.1111/j.1467789X.2008.00541.x.
[9]	International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy[J]. Diabetes Care, 2010, 33(3): 676-682. DOI: 10.2337/dc09-1848.
[10]	Sun D, Zhang T, Su S, et al. Body mass index drives changes in DNA methylation: a longitudinal study[J]. Circ Res, 2019, 125(9): 824-833. DOI: 10.1161/CIRCRESAHA.119.315397.
[11]	Richmond RC, Sharp GC, Ward ME, et al. DNA methylation and BMI: investigating identified methylation sites at HIF3A in a causal framework[J]. Diabetes, 2016, 65(5): 1231-1244. DOI: 10.2337/db15-0996.
[12]	Howe CG, Cox B, Fore R, et al. Maternal gestational diabetes mellitus and newborn DNA methylation: findings from the pregnancy and childhood epigenetics consortium[J]. Diabetes Care, 2020, 43(1): 98-105. DOI: 10.2337/dc19-0524.
[13]	Zhu W, Shen Y, Liu J, et al. Epigenetic alternations of microRNAs and DNA methylation contribute to gestational diabetes mellitus[J]. J Cell Mol Med, 2020, 24(23): 13899-13912. DOI: 10.1111/jcmm.15984.
[14]	Rong C, Cui X, Chen J, et al. DNA methylation profiles in placenta and its association with gestational diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 2015, 123(5): 282-288. DOI: 10.1055/s-0034-1398666.
[15]	李嘉佩, 赵维纲, 付勇, 等. MTNR1B基因DNA甲基化与妊娠期糖尿病及妊娠期间糖脂代谢关系的研究[J]. 中华临床营养杂志, 2019, 27(3): 138-143. DOI:10.3760cma.j.issn.1674-635X.2019.03.003. Li JP, Zhao WG, Fu Y, et al. The role of MTNR1B gene DNA methylation in gestational diabetes mellitus[J]. Chinese Journal of Clinical Nutrition, 2019, 27(3): 138-143. DOI:10.3760cma.j.issn.1674-635X.2019.03.003.
[16]	Millstein J, Zhang B, Zhu J, et al. Disentangling molecular relationships with a causal inference test[J]. BMC Genet, 2009, 10: 23. DOI: 10.1186/1471-2156-10-23.
[17]	Liu Y, Aryee MJ, Padyukov L, et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in rheumatoid arthritis[J]. Nat Biotechnol, 2013, 31(2): 142-7. DOI: 10.1038/nbt.2487.
[18]	Kular L, Liu Y, Ruhrmann S, et al. DNA methylation as a mediator of HLA-DRB1a15: 01 and a protective variant in multiple sclerosis[J]. Nat Commun, 2018, 9(1): 2397. DOI: 10.1038/s41467-018-04732-5.
[19]	Dustin T, Teppei Y, Kentaro H, et al. Mediation: R package for causal mediation analysis[J]. Journal of Statistical Software, 2014, 59(5): 17831. DOI: 10.18637/jss.v059.i05.
[20]	Valeri L, Vanderweele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros[J]. Psychol Methods, 2013, 18(2): 137-150. DOI: 10.1037/a0031034.
[21]	Du P, Zhang X, Huang CC, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis[J]. BMC Bioinformatics, 2010, 11: 587. DOI: 10.1186/1471-2105-11-587.
[22]	Vanderweele TJ, Vansteelandt S. Odds ratios for mediation analysis for a dichotomous outcome[J]. Am J Epidemiol, 2010, 172(12): 1339-1348. DOI: 10.1093/aje/kwq332.
[23]	VanderWeele TJ, Vansteelandt S. Mediation analysis with multiple mediators[J]. Epidemiol Methods, 2014, 2(1): 95-115. DOI: 10.1515/em-2012-0010.
[24]	Reichetzeder C, Putra SED, Pfab T, et al. Increased global placental DNA methylation levels are associated with gestational diabetes[J]. BioMed Central, 2016, 8: 82. DOI: 10.1186/s13148-016-0247-9.
[25]	Kafka A, Tomas D, Beroš V, et al. Brain metastases from lung cancer show increased expression of DVL1, DVL3 and beta-catenin and down-regulation of E-cadherin[J]. Int J Mol Sci, 2014, 15(6): 10635-10651. DOI: 10.3390/ijms150610635.
[26]	辛先祥. 前列腺癌甲基化相关基因生物信息筛选和候选基因VWA1甲基化与前列腺癌关系研究[D]. 广西: 广西医科大学, 2015. Xin XX. Bioinformation screening of methylation related genes in prostate cancer and the relationship between VWA1 methylation and prostate cancer[D]. Guangxi: Guangxi Medical University, 2015.
[27]	Hui Y, Xia G. TP73 is a credible biomarker for predicting clinical progression and prognosis in cervical cancer patients[J]. Biosci Rep, 2019, 39(8): BSR20190095. DOI: 10.1042/BSR20190095.
[28]	Feng H, Sui L, Du M, et al. Meta-analysis of TP73 polymorphism and cervical cancer[J]. Genet Mol Res, 2017, 16(1): gmr16016571. DOI: 10.4238/gmr16016571.
[29]	De Fátima Senra CM, Madeiros CCH, de LJL, et al. Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles[J]. Mutat Res, 2017, 773: 161-173. DOI: 10.1016/j.mrrev.2017.06.002.